{"ticker": {"uuid": "2e545092-abf4-43e8-8732-4098c61eb88c", "symbol": "IRD", "name": "Opus Genetics, Inc.", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMigAJBVV95cUxPV1hqSFhQM3VfYlNsdldfeVQ1dEdNNzI3S1RTaFJNSThrOXlPSWpMTlR5WWVxNnNsTzhTVGVvTE94R18wa1A0OUdFczBlcTIzeUFBZUt6VVJJMjNqNks3dmRUSzB4cE40anpNekJwUXAwcTFEcVh4QVZCYURXY2w4b2thdk5KZ3ZJMnI1REJObXo5UDdISXVCU1Z2ZVZoVmJpbnEzaDVWVmpGQVNFZzRXYnp0SWRRWWZGSnZnWlJ4aEloNmJBNGRMVFRjb3ZRbmV3QXF5S0pvTV9xNnpaMWV1Z1ZtM3lPdV9RcEdURHlfZFphdjlicEJndW0ybHNBa205?oc=5", "source_name": "The Globe and Mail", "published_at": "2026-07-13T03:32:00+00:00", "published_display": "13 Jul 2026 03:32", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Price to earnings forward of Opus Genetics, Inc. \u2013 NASDAQ:IRD", "summary": "", "url": "https://news.google.com/rss/articles/CBMioAFBVV95cUxOUTRTSlFjb2V6Ni0tcmliVnRnUWhfLVUtOG1xNWRuTldMVnk1STZfM1pJMEpOOE5VM1RmRi1CREJaRUlLdm9RUGhFc0pxY3VEMDFxVkRHSUV1WmRtaHBhSWF6SUhRMUhFd1M0M0Y3b2YwdUFlNXJjOWJtWkVyYkhRM1B6aEJEbTV4NE1ja0tyOGtXanFNRWRWVEpSQS0zcUtv?oc=5", "source_name": "TradingView", "published_at": "2026-07-09T20:59:16+00:00", "published_display": "09 Jul 2026 20:59", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Opus Genetics: The Future Lies In The Success Of The AAV Delivery Platform (NASDAQ:IRD)", "summary": "", "url": "https://news.google.com/rss/articles/CBMitAFBVV95cUxQRVhTS2lXT2V6NnRlTXo4M2d1bjBiaEljb2U2MzJ3YkRlX2pBZXc4eXl1YU05MTNrc0tVSDEwMk8ybjNkc0dCMlFrdDVWd1ZoSlU3eHZSbUotbXZYa1dTbldNVzJIUnlzeTR2OXFQVjVMc1dDX3NLd29PWVN6Mm1BUC1SZWVwa2JldGZ1dkNmWGN2ZmotMkNQOVUxZHhIR1JyRURzczNEc0MydmxGSUs3TDNqS3c?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-06-03T07:00:00+00:00", "published_display": "03 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Opus Genetics, Inc. (IRD) Reports Q1 Loss, Misses Revenue Estimates", "summary": "", "url": "https://news.google.com/rss/articles/CBMimgFBVV95cUxPSWtqTG9mQTRUUWVwdlJJbjN1clozeXB1dGlmbDhONkpYb0g0YlkzMTAtdUhBdTNGS2VQMDctS0NUUVdrc0xTaGZHX2dXNVBUX0x1aHdjTmxwQVpDNlB0RGFyMThOeVZrMDdMOUdLTFNvZFN1dmVWdHNTbHdXdnFJdlVFTUQ4dGRvS0k0YjR6QlM3X0h6SWVsOTJB?oc=5", "source_name": "Market source", "published_at": "2026-05-12T07:00:00+00:00", "published_display": "12 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 18, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Here is Why Opus Genetics (IRD) is One of the Best Performing NASDAQ Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNVXhhaF91THc1M0VGS3d0bFc1RkpsbUMtbkZnZzNNVGhheUNXLXVJTnRTQ2ZCbG1YZnJaTDlXWFBSU0pLbkRSS2hfc3RyRFpKY3RjS3RBeHU4SzhXNUhudF9oSFRvbWNlSkdtSnFoMFpxYjY2bElFLVh1VlVtSFgydlFHVk1ESU9aajk2TS1SRkFTSlJ6?oc=5", "source_name": "Market source", "published_at": "2026-05-05T07:00:00+00:00", "published_display": "05 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Opus Genetics (Nasdaq:IRD) - Stock Analysis", "summary": "Opus Genetics (Nasdaq:IRD) is a clinical-stage biopharmaceutical company focused on gene therapies for inherited retinal diseases. The stock is currently trading at US$5.00, with analysts setting a price target of US$10.07, indicating it is undervalued. The company faces risks su", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ird/opus-genetics", "source_name": "Simply Wall Street", "published_at": "2026-04-26T23:08:51", "published_display": "26 Apr 2026 23:08", "sentiment": "positive", "sentiment_pct": 61, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Oppenheimer Initiates Coverage on Opus Genetics (NASDAQ:IRD)", "summary": "Oppenheimer has initiated coverage on Opus Genetics (NASDAQ:IRD) with an \"outperform\" rating and a $10.00 price target, suggesting a potential upside of nearly 99%. This comes amidst several other analyst \"buy\" or \"strong-buy\" ratings and significant insider and institutional buy", "url": "https://www.marketbeat.com/instant-alerts/oppenheimer-initiates-coverage-on-opus-genetics-nasdaqird-2026-03-16/", "source_name": "MarketBeat", "published_at": "2026-03-14T12:40:56", "published_display": "14 Mar 2026 12:40", "sentiment": "positive", "sentiment_pct": 80, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Opus Genetics, Inc. (IRD) Reports Q4 Loss, Tops Revenue Estimates", "summary": "", "url": "https://news.google.com/rss/articles/CBMigAFBVV95cUxOS0RWcUt5bmNkTDRFNnZiQUFiTW5UXzdEdUoxcHlRZGhxYVBWVzVuX1BqVnpzczVQbDNOUW1SQWN1TUNqZThyTUNQNDVYUUhaTmJUd1JrZG4xVk5ad3ZjZndIUkZ4cUxqTXFlQ2paTmtIdV96dDFvbjEwNldUSUZzZA?oc=5", "source_name": "Market source", "published_at": "2026-03-10T07:00:00+00:00", "published_display": "10 Mar 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Opus Genetics: Asymmetric Upside With LCA5 And BEST1 (NASDAQ:IRD)", "summary": "", "url": "https://news.google.com/rss/articles/CBMilwFBVV95cUxQR043d3JsVG42ZEdRaGVLQVFaQkNRUVU0WnJYbktaT2d3RTFGbm8tT000bEpTSm9WTGFfSGl5NnY3MVhfSVJyUGlwcEY4cDYyT01EUjJ5OTR1d3pQYWRsaGkxbDZiMjdtM1VHZW5BRVgxYnZadTNlSjVqVW5rZERnaDhFZ2tIWEY4NTdQeFFFSmNTelJFQU1J?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-02-22T08:00:00+00:00", "published_display": "22 Feb 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Revenues Not Telling The Story For Opus Genetics, Inc. (NASDAQ:IRD) After Shares Rise 43%", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-02-07T08:00:00+00:00", "published_display": "07 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Opus Genetics, Inc.'s (NASDAQ:IRD) large institutional owners must be happy as stock continues to impress, up 12% over the past week", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2025-11-29T08:00:00+00:00", "published_display": "29 Nov 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "OCUP Stock Price, News & Analysis", "summary": "Ocuphire Pharma, Inc. (OCUP) historically focused on clinical-stage ophthalmic therapies before combining with Opus Genetics, Inc. The combined entity, now operating as Opus Genetics, Inc. and trading under \"IRD\" on Nasdaq, focuses on gene therapies for inherited retinal diseases", "url": "https://www.stocktitan.net/overview/OCUP/", "source_name": "Stock Titan", "published_at": "2025-04-25T19:27:46", "published_display": "25 Apr 2025 19:27", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ophthalmic Biopharmaceutical Ocuphire Pharma Shifts Focus To Gene Therapy Through Opus Genetics Stock Deal", "summary": "Ocuphire Pharma, Inc. announced an all-stock acquisition of Opus Genetics, Inc., a clinical-stage gene therapy company for inherited retinal diseases (IRDs). This merger will shift Ocuphire's focus to gene therapy, with the combined company being renamed Opus Genetics and trading", "url": "https://finance.yahoo.com/news/ophthalmic-biopharmaceutical-ocuphire-pharma-shifts-192545264.html", "source_name": "Market source", "published_at": "2024-10-23T04:10:58", "published_display": "23 Oct 2024 04:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 96, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ocuphire Pharma Merges with Opus Genetics, Renamed Opus Genetics", "summary": "Ocuphire Pharma has merged with Opus Genetics in an all-stock transaction, forming a new biotech company focused on gene therapies for inherited retinal diseases. The combined entity will be renamed Opus Genetics, Inc. and trade under the ticker 'IRD', with plans for significant ", "url": "https://finance.yahoo.com/news/ocuphire-pharma-merges-opus-genetics-213102859.html", "source_name": "Market source", "published_at": "2024-10-23T00:00:00", "published_display": "23 Oct 2024 00:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Price to earnings forward of Opus Genetics, Inc. \u2013 NASDAQ:IRD", "summary": "", "url": "https://news.google.com/rss/articles/CBMioAFBVV95cUxOUTRTSlFjb2V6Ni0tcmliVnRnUWhfLVUtOG1xNWRuTldMVnk1STZfM1pJMEpOOE5VM1RmRi1CREJaRUlLdm9RUGhFc0pxY3VEMDFxVkRHSUV1WmRtaHBhSWF6SUhRMUhFd1M0M0Y3b2YwdUFlNXJjOWJtWkVyYkhRM1B6aEJEbTV4NE1ja0tyOGtXanFNRWRWVEpSQS0zcUtv?oc=5", "source_name": "TradingView", "published_at": "2026-07-09T20:59:16+00:00", "published_display": "09 Jul 2026 20:59", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Opus Genetics: The Future Lies In The Success Of The AAV Delivery Platform (NASDAQ:IRD)", "summary": "", "url": "https://news.google.com/rss/articles/CBMitAFBVV95cUxQRVhTS2lXT2V6NnRlTXo4M2d1bjBiaEljb2U2MzJ3YkRlX2pBZXc4eXl1YU05MTNrc0tVSDEwMk8ybjNkc0dCMlFrdDVWd1ZoSlU3eHZSbUotbXZYa1dTbldNVzJIUnlzeTR2OXFQVjVMc1dDX3NLd29PWVN6Mm1BUC1SZWVwa2JldGZ1dkNmWGN2ZmotMkNQOVUxZHhIR1JyRURzczNEc0MydmxGSUs3TDNqS3c?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-06-03T07:00:00+00:00", "published_display": "03 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Opus Genetics, Inc. (IRD) Reports Q1 Loss, Misses Revenue Estimates", "summary": "", "url": "https://news.google.com/rss/articles/CBMimgFBVV95cUxPSWtqTG9mQTRUUWVwdlJJbjN1clozeXB1dGlmbDhONkpYb0g0YlkzMTAtdUhBdTNGS2VQMDctS0NUUVdrc0xTaGZHX2dXNVBUX0x1aHdjTmxwQVpDNlB0RGFyMThOeVZrMDdMOUdLTFNvZFN1dmVWdHNTbHdXdnFJdlVFTUQ4dGRvS0k0YjR6QlM3X0h6SWVsOTJB?oc=5", "source_name": "Market source", "published_at": "2026-05-12T07:00:00+00:00", "published_display": "12 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 18, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Here is Why Opus Genetics (IRD) is One of the Best Performing NASDAQ Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNVXhhaF91THc1M0VGS3d0bFc1RkpsbUMtbkZnZzNNVGhheUNXLXVJTnRTQ2ZCbG1YZnJaTDlXWFBSU0pLbkRSS2hfc3RyRFpKY3RjS3RBeHU4SzhXNUhudF9oSFRvbWNlSkdtSnFoMFpxYjY2bElFLVh1VlVtSFgydlFHVk1ESU9aajk2TS1SRkFTSlJ6?oc=5", "source_name": "Market source", "published_at": "2026-05-05T07:00:00+00:00", "published_display": "05 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Opus Genetics (Nasdaq:IRD) - Stock Analysis", "summary": "Opus Genetics (Nasdaq:IRD) is a clinical-stage biopharmaceutical company focused on gene therapies for inherited retinal diseases. The stock is currently trading at US$5.00, with analysts setting a price target of US$10.07, indicating it is undervalued. The company faces risks su", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ird/opus-genetics", "source_name": "Simply Wall Street", "published_at": "2026-04-26T23:08:51", "published_display": "26 Apr 2026 23:08", "sentiment": "positive", "sentiment_pct": 61, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Oppenheimer Initiates Coverage on Opus Genetics (NASDAQ:IRD)", "summary": "Oppenheimer has initiated coverage on Opus Genetics (NASDAQ:IRD) with an \"outperform\" rating and a $10.00 price target, suggesting a potential upside of nearly 99%. This comes amidst several other analyst \"buy\" or \"strong-buy\" ratings and significant insider and institutional buy", "url": "https://www.marketbeat.com/instant-alerts/oppenheimer-initiates-coverage-on-opus-genetics-nasdaqird-2026-03-16/", "source_name": "MarketBeat", "published_at": "2026-03-14T12:40:56", "published_display": "14 Mar 2026 12:40", "sentiment": "positive", "sentiment_pct": 80, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Opus Genetics, Inc. (IRD) Reports Q4 Loss, Tops Revenue Estimates", "summary": "", "url": "https://news.google.com/rss/articles/CBMigAFBVV95cUxOS0RWcUt5bmNkTDRFNnZiQUFiTW5UXzdEdUoxcHlRZGhxYVBWVzVuX1BqVnpzczVQbDNOUW1SQWN1TUNqZThyTUNQNDVYUUhaTmJUd1JrZG4xVk5ad3ZjZndIUkZ4cUxqTXFlQ2paTmtIdV96dDFvbjEwNldUSUZzZA?oc=5", "source_name": "Market source", "published_at": "2026-03-10T07:00:00+00:00", "published_display": "10 Mar 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Opus Genetics: Asymmetric Upside With LCA5 And BEST1 (NASDAQ:IRD)", "summary": "", "url": "https://news.google.com/rss/articles/CBMilwFBVV95cUxQR043d3JsVG42ZEdRaGVLQVFaQkNRUVU0WnJYbktaT2d3RTFGbm8tT000bEpTSm9WTGFfSGl5NnY3MVhfSVJyUGlwcEY4cDYyT01EUjJ5OTR1d3pQYWRsaGkxbDZiMjdtM1VHZW5BRVgxYnZadTNlSjVqVW5rZERnaDhFZ2tIWEY4NTdQeFFFSmNTelJFQU1J?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-02-22T08:00:00+00:00", "published_display": "22 Feb 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Revenues Not Telling The Story For Opus Genetics, Inc. (NASDAQ:IRD) After Shares Rise 43%", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-02-07T08:00:00+00:00", "published_display": "07 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Opus Genetics, Inc.'s (NASDAQ:IRD) large institutional owners must be happy as stock continues to impress, up 12% over the past week", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2025-11-29T08:00:00+00:00", "published_display": "29 Nov 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "OCUP Stock Price, News & Analysis", "summary": "Ocuphire Pharma, Inc. (OCUP) historically focused on clinical-stage ophthalmic therapies before combining with Opus Genetics, Inc. The combined entity, now operating as Opus Genetics, Inc. and trading under \"IRD\" on Nasdaq, focuses on gene therapies for inherited retinal diseases", "url": "https://www.stocktitan.net/overview/OCUP/", "source_name": "Stock Titan", "published_at": "2025-04-25T19:27:46", "published_display": "25 Apr 2025 19:27", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ophthalmic Biopharmaceutical Ocuphire Pharma Shifts Focus To Gene Therapy Through Opus Genetics Stock Deal", "summary": "Ocuphire Pharma, Inc. announced an all-stock acquisition of Opus Genetics, Inc., a clinical-stage gene therapy company for inherited retinal diseases (IRDs). This merger will shift Ocuphire's focus to gene therapy, with the combined company being renamed Opus Genetics and trading", "url": "https://finance.yahoo.com/news/ophthalmic-biopharmaceutical-ocuphire-pharma-shifts-192545264.html", "source_name": "Market source", "published_at": "2024-10-23T04:10:58", "published_display": "23 Oct 2024 04:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 96, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ocuphire Pharma Merges with Opus Genetics, Renamed Opus Genetics", "summary": "Ocuphire Pharma has merged with Opus Genetics in an all-stock transaction, forming a new biotech company focused on gene therapies for inherited retinal diseases. The combined entity will be renamed Opus Genetics, Inc. and trade under the ticker 'IRD', with plans for significant ", "url": "https://finance.yahoo.com/news/ocuphire-pharma-merges-opus-genetics-213102859.html", "source_name": "Market source", "published_at": "2024-10-23T00:00:00", "published_display": "23 Oct 2024 00:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMigAJBVV95cUxPV1hqSFhQM3VfYlNsdldfeVQ1dEdNNzI3S1RTaFJNSThrOXlPSWpMTlR5WWVxNnNsTzhTVGVvTE94R18wa1A0OUdFczBlcTIzeUFBZUt6VVJJMjNqNks3dmRUSzB4cE40anpNekJwUXAwcTFEcVh4QVZCYURXY2w4b2thdk5KZ3ZJMnI1REJObXo5UDdISXVCU1Z2ZVZoVmJpbnEzaDVWVmpGQVNFZzRXYnp0SWRRWWZGSnZnWlJ4aEloNmJBNGRMVFRjb3ZRbmV3QXF5S0pvTV9xNnpaMWV1Z1ZtM3lPdV9RcEdURHlfZFphdjlicEJndW0ybHNBa205?oc=5", "source_name": "The Globe and Mail", "published_at": "2026-07-13T03:32:00+00:00", "published_display": "13 Jul 2026 03:32", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 104, "total_relevant": 22, "sentiment_summary": {"positive": 5, "negative": 3, "neutral": 14, "score": 53, "total": 22, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "earnings", "primary_label": "Earnings", "confidence": 76, "events": [{"event": "earnings", "label": "Earnings", "weight": 5.36, "count": 12}, {"event": "general", "label": "Market update", "weight": 4.55, "count": 7}, {"event": "analyst", "label": "Analyst action", "weight": 1.1, "count": 2}, {"event": "deals", "label": "Deals and strategy", "weight": 0.55, "count": 1}], "positive_events": 5, "negative_events": 3}, "market_context": {"has_market_context": true, "latest_close": 3.92, "latest_week": "2026-07-10", "one_week_move": -7.3, "four_week_move": -3.0, "twelve_week_move": -31.8, "trend_signal": "1", "trend_label": "Trend active", "trend_tone": "positive", "market_dynamics": -0.785619, "market_dynamics_buy_signal": false, "relative_strength": 16.377656, "fair_value_gap": 73.2, "fair_value_label": "Materially above fair value", "fair_value_tone": "negative", "expectation_direction": "positive", "expectation_probability": 60.2794, "reaction_label": "Price reacting lower", "reaction_tone": "negative", "market_sentence": "-7.3% over one week, -3.0% over four weeks, trend active, and materially above fair value."}, "interpretation": {"label": "Price moving ahead of tone", "tone": "negative", "classification": "price_leads_news", "summary": "Price is moving more forcefully than the current news tone suggests.", "confidence": 60, "badges": [], "opportunities": [], "risks": [], "event_label": "Earnings", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Market source", "count": 10}, {"label": "simplywall.st", "count": 4}, {"label": "TradingView", "count": 2}, {"label": "Seeking Alpha", "count": 2}, {"label": "The Globe and Mail", "count": 1}, {"label": "Simply Wall Street", "count": 1}, {"label": "MarketBeat", "count": 1}, {"label": "Stock Titan", "count": 1}], "tiers": [{"label": "Direct company coverage", "count": 13}, {"label": "Industry context", "count": 9}, {"label": "Sector context", "count": 0}], "events": [{"label": "Earnings", "count": 12}, {"label": "Market update", "count": 7}, {"label": "Analyst action", "count": 2}, {"label": "Deals and strategy", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "53/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Price moving ahead of tone", "tone": "negative", "text": "Price is moving more forcefully than the current news tone suggests."}, {"label": "Primary event", "value": "Earnings", "tone": "neutral", "text": "76/100 classification confidence."}, {"label": "Company focus", "value": "13", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "2", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend active", "tone": "positive", "text": "-7.3% over one week, -3.0% over four weeks, trend active, and materially above fair value."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "Price to earnings forward of Opus Genetics, Inc. \u2013 NASDAQ:IRD"}], "updated_at": "2026-07-17T04:44:50.240160+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}